



Background: The endocannabinoid system is a potential regulator of tumour biology; however, the expression and clinical significance of cannabinoid receptors in clear cell RCC (ccRCC) remain poorly understood.

Aim: To characterize **CB1 and CB2 expression** in ccRCC and evaluate their association with clinicopathological features and clinical outcomes.



Study Design



Key Findings

Distinct cannabinoid receptor signature in ccRCC



CB1
Lower in
Tumor





CB2
Higher in
Tumor



Differential Expression of Cannabinoid receptors in ccRCC

a) CB1 expression

Normal
n=13








Tumor
n=90






IHC revealed a reciprocal cannabinoid receptor pattern in ccRCC

Reduced CB1 and increased CB2 expression compared with normal kidney.

b) CB2 expression



Molecular Validation



A distinct CB1 regulatory pattern




CB1 Protein: Significant.
CB1 mRNA: Non-significant
Suggesting post-transcriptional regulation of CB1

Clinicopathological Association

- Higher CB2 expression associated with male sex, $P=0.010$
- Higher CB2 expression associated with higher tumor grade, $P=0.040$
- No significant association was found between CB1 expression and clinicopathological variables

Overall Survival

Survival proportions of CB1 and CB2 low vs high expressions



Conclusion

ccRCC exhibits a reproducible low CB1 and high CB2 molecular phenotype

Overexpression of CB2 is associated with higher tumor grade and male sex

CB2 may represent a potential biomarker and candidate therapeutic target in RCC